Palade Particles, 1955

Electron microscopy led to the first identification of what would later be known as ribosomes.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ROUGH ER: In 1966, a decade after first describing granules within cells that would come to be known as ribosomes, George Palade generated this transmission electron micrograph of the guinea pig pancreas illustrating the endoplasmic reticulum studded with ribosomes. COURTESY OF YALE UNIVERSITY SCHOOL OF MEDICINEAs biologist James Rothman took the stage in Stockholm last year to accept a Nobel Prize for his work on vesicle transport, he gave credit to the man who used to occupy his office at Yale University. “Certainly the story of the work that led to my contributions begins with George Palade,” Rothman said. A grandfather of the field of cell biology and the founder of Rothman’s department, Palade discovered a process of intracellular transport—the movement of proteins from the endoplasmic reticulum (ER) to the Golgi apparatus and then into secretory vesicles.

In 1974, Palade himself took the stage to deliver his own Nobel lecture. The foundation for much of his work was electron microscopy (EM), which Palade used to visualize the components of the cell. During the 1950s, as a researcher at the Rockefeller Institute for Medical Research (now Rockefeller University) in New York City, Palade was surrounded by the giants of EM—Keith Porter, Albert Claude, and others. As Palade described in his Nobel lecture, their advances in EM led to a “near avalanche of discoveries, rediscoveries, and redefinitions of subcellular components” in the early 1950s.

During this time, Palade and many of his colleagues were particularly interested in the pancreatic acinar cell, a veritable factory of protein synthesis and secretion. With advances in thin sectioning, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies